| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Marketing > Efficient Market Hypothesis: Myth of Reality? |
|
Advice You - Efficient Market Hypothesis: Myth of Reality?
The efficient market hypothesis (EMH) was promoted by Eugene Fama in the 1960. In his classic paper Fama (1970) defined market in which prices always fully reflect available information as “efficient”.While According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product this definition reflects the main idea of the EMH it might be extended to explain the underlying assumption. For example Malkiel (1992) proposed the following definition: A capital market is said to be ef ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in icient to if it fully and correctly reflects all relevant information in determining security prices. Therefore, more formally, the market is efficient with respect to some information set. ..if security p lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. rices would be unaffected by revealing that information to all participants. Moreover, efficiency implies that it is impossible to make economic profits by trading on the basis of the defined information se here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe (Papers4you.com, 2006). As it follows from the Malkiel (1992) definition if the market is efficient the company market value should be an unbiased estimate of the true value. Nevertheless it is important d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro o stress that: 1. Market efficiency does not require that market price is equal to the true value 2. There is an equal probability that stocks over or under valued at any point in the time 3. And finally ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc , investors should not be able to consistently identify under or over valued stocks using any investment strategy ( Damodaran, 2006). What are the implications of the market efficiency from the individual easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi nvestor perspective?
Firstly, equity research is costly and provides no benefits. Secondly strategies that have minimal execution costs such as randomly diversified portfolio or indexing to the market wou nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ld be superior to any other investment strategy. Thirdly, a strategy that has minimum transaction costs should provide higher returns in the long run (Damodaran, 2006). Nevertheless it is important to stre and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s that markets are not efficient due to their nature, but they are driven to efficiency by the actions of the investors. Therefore Roberts(1967) distinguished among three forms of the market efficiency: 1. ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi Weak form: the information set includes only historic data. 2. Semi strong: the information set includes publicly available information. 3. Strong form: the information set includes all information know t ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a o any market participant and includes private information. Obviously in reality, investors have access to different information sets. While trading which is based on the insider information is prosecuted, dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod nalysis and interpretation of the publicly available information requires specific knowledge and skills (Papers4you.com, 2006). Therefore the efficient market should be seen as a self correcting mechanism, cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin where inefficiencies appear at regular intervals but disappear almost instantaneously as investors find and trade on them. EMH has wide applications in the financial markets, since it is easily extended t tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen the valuation of companies , market failures such as an Enron Case, or performance analysis of the mutual funds. The traditional analysis of the market efficiency is based on the analysis of the anomalie t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel such as Peso Effect in the foreign exchange market or devoted to the predictability of the stock returns. References Damodaran )nline (2006) “MARKET EFFICIENCY - DEFINITION AND TESTS”, Available from: ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust http://pages.stern.nyu.edu/~ADAMODAR/New_Home_Page/invemgmt/effdefn.htm [17/06/2006] Fama E. F., 1970, Efficient capitalmarkets: Areviewof theory and empiricalwork, Journal of Finance, 25, 383–417. Malkie y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products B (1992) Efficient market hypothesis. In NewMan P.M. Milgate ,and J Eawells (eds). The new Palgrave dictionary of Money and Finance. Papers For You (2006) "C/F/94. Validity of the Efficient Market Hypothe . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de sis", Available from http://www.coursework4you.co.uk/sprtfina2.htm [17/06/2006] Papers For You (2006) "E/F/38. Efficient market hypothesis: theory and implications", Available from http://www.coursework4yo elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip .co.uk/sprtfina2.htm [18/06/2006] Robersts, H. 1967. Statistical versus clinical predictions of the stock markets. Unpublished manuscript, Center for research in Security Prices, University of Chicago, May tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:From Desperate Housewife to PR Diva in 9 Life Altering Steps - Tips for Business Owner Hopefuls Volunteer Management: Grievance and Complaints Improving Your Search Engine Ranking
|